https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-april-23-2026/ 2026-04-23T21:14:13Z Pharminent en Rare Disease & Gene Therapy Digest • April 23, 2026 2026-04-23T21:14:10Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-23-2026/ 2026-04-23T21:02:27Z Pharminent en Strategic News Watch • April 23, 2026 2026-04-23T21:02:24Z Blog https://pharminent.com/sanofi-posts-upbeat-sales-as-rd-pressure-builds/ 2026-04-23T20:37:15Z Pharminent en Sanofi posts upbeat sales as R&D pressure builds 2026-04-23T15:02:00Z Blog https://pharminent.com/bbot-shakes-up-leadership-as-ras-competitors-get-more-visibility/ 2026-04-23T20:37:17Z Pharminent en BBOT shakes up leadership as RAS competitors get more visibility 2026-04-23T14:58:54Z Blog https://pharminent.com/novo-says-oral-semaglutide-works-in-diabetic-kids/ 2026-04-23T20:37:19Z Pharminent en Novo says oral semaglutide works in diabetic kids 2026-04-23T14:29:35Z Blog https://pharminent.com/sanofi-defends-dupixent-patents-but-execs-insist-it-has-nothing-to-do-with-ceo-change/ 2026-04-23T20:37:21Z Pharminent en Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change 2026-04-23T13:49:04Z Blog https://pharminent.com/cms-and-fda-announce-rapid-coverage-pathway-to-accelerate-patient-access-to-life-changing-medical-devices/ 2026-04-23T20:37:22Z Pharminent en CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices 2026-04-23T12:50:46Z Blog https://pharminent.com/unnamed-pharma-files-citizen-petition-targeting-fdas-trove-of-rejection-letters/ 2026-04-23T20:37:24Z Pharminent en Unnamed pharma files citizen petition targeting FDA's trove of rejection letters 2026-04-23T11:56:31Z Blog https://pharminent.com/roche-insists-amylin-obesity-drug-still-valuable-for-patients-who-dont-want-side-effects/ 2026-04-23T20:37:25Z Pharminent en Roche insists amylin obesity drug still valuable for patients who 'don't want side effects' 2026-04-23T11:55:46Z Blog https://pharminent.com/aan-2026-jj-kyverna-capricor-and-praxis-showcase-practice-changing-data/ 2026-04-23T20:37:26Z Pharminent en AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data 2026-04-23T11:34:39Z Blog https://pharminent.com/minnesotas-340b-hospitals-make-one-billion-more-from-340b-than-they-spend-on-uncompensated-care/ 2026-04-23T20:37:28Z Pharminent en Minnesota's 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care 2026-04-23T11:00:00Z Blog https://pharminent.com/sanofi-receives-fda-approval-for-tzield-in-paediatric-diabetes/ 2026-04-23T20:37:29Z Pharminent en Sanofi receives FDA approval for Tzield in paediatric diabetes 2026-04-23T10:05:43Z Blog https://pharminent.com/abbvie-opts-for-north-carolina-to-house-1-4bn-manufacturing-site/ 2026-04-23T20:37:29Z Pharminent en AbbVie opts for North Carolina to house $1.4bn manufacturing site 2026-04-23T09:36:58Z Blog https://pharminent.com/msd-teams-up-with-google-cloud-on-agentic-ai-transformation/ 2026-04-23T20:37:30Z Pharminent en MSD teams up with Google Cloud on agentic AI transformation 2026-04-23T09:30:13Z Blog https://pharminent.com/abbvie-makes-record-investment-in-north-carolina-plant/ 2026-04-23T20:37:30Z Pharminent en AbbVie makes record investment in North Carolina plant 2026-04-23T08:37:34Z Blog https://pharminent.com/fda-releases-congressional-justification-for-fy-2027-budget-including-proposal-regarding-interchangeability-of-biosimilars/ 2026-04-23T16:44:15Z Pharminent en FDA Releases Congressional Justification for FY 2027 Budget, Including Proposal Regarding Interchangeability of Biosimilars 2026-04-22T21:21:33Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-22-2026/ 2026-04-22T17:48:50Z Pharminent en Strategic News Watch • April 22, 2026 2026-04-22T17:48:47Z Blog https://pharminent.com/medicare-weight-loss-drug-pilot-on-ice-as-insurers-decline-to-contribute/ 2026-04-23T16:44:18Z Pharminent en Medicare weight loss drug pilot on ice as insurers decline to contribute 2026-04-22T16:28:04Z Blog https://pharminent.com/revolution-drug-shows-promise-in-early-pancreatic-cancer/ 2026-04-23T16:44:20Z Pharminent en Revolution drug shows promise in early pancreatic cancer 2026-04-22T15:50:00Z Blog https://pharminent.com/moderna-after-losing-us-funding-rebounds-to-start-mrna-bird-flu-vaccine-trial/ 2026-04-22T16:19:02Z Pharminent en Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial 2026-04-22T15:21:00Z Blog https://pharminent.com/trumps-psychedelics-push-a-mixed-blessing-for-neuropsychiatric-companies-patients/ 2026-04-22T16:19:05Z Pharminent en Trump's psychedelics push a mixed blessing for neuropsychiatric companies, patients 2026-04-22T14:59:05Z Blog https://pharminent.com/neurology-biomanufacturing-start-ups-bag-uk-ai-funding/ 2026-04-22T16:19:08Z Pharminent en Neurology, biomanufacturing start-ups bag UK AI funding 2026-04-22T13:21:48Z Blog https://pharminent.com/ionis-antisense-drug-stabilizes-ultra-rare-disease-ahead-of-fda-decision/ 2026-04-22T16:19:09Z Pharminent en Ionis' antisense drug stabilizes ultra-rare disease ahead of FDA decision 2026-04-22T13:18:29Z Blog https://pharminent.com/lilly-exits-rigel-alliance-adding-to-ripk1-scrap-heap/ 2026-04-22T16:19:11Z Pharminent en Lilly exits Rigel alliance, adding to RIPK1 scrap heap 2026-04-22T12:55:40Z Blog https://pharminent.com/fda-delays-decision-on-sanofis-subcutaneous-sarclisa/ 2026-04-22T16:19:13Z Pharminent en FDA delays decision on Sanofi's subcutaneous Sarclisa 2026-04-22T12:25:24Z Blog https://pharminent.com/msd-backed-ray-locks-in-125m-to-back-eye-drug-pipeline/ 2026-04-22T16:19:15Z Pharminent en MSD-backed Ray locks in $125m to back eye drug pipeline 2026-04-22T11:57:43Z Blog https://pharminent.com/new-data-build-case-for-roches-oral-btk-drug-for-ms/ 2026-04-22T16:19:16Z Pharminent en New data build case for Roche's oral BTK drug for MS 2026-04-22T11:36:30Z Blog https://pharminent.com/pivotal-trial-of-modernas-h5n1-bird-flu-jab-gets-underway/ 2026-04-22T16:19:17Z Pharminent en Pivotal trial of Moderna's H5N1 bird flu jab gets underway 2026-04-22T10:30:55Z Blog https://pharminent.com/bioaegis-and-prenosis-partner-for-inflammatory-disease-therapies/ 2026-04-22T16:19:18Z Pharminent en BioAegis and Prenosis partner for inflammatory disease therapies 2026-04-22T09:57:07Z Blog https://pharminent.com/bioaegis-and-prenosis-partner-for-inflammatory-disease-therapies-2/ 2026-04-22T16:19:18Z Pharminent en BioAegis and Prenosis partner for inflammatory disease therapies 2026-04-22T09:31:46Z Blog https://pharminent.com/medicare-obesity-drug-pilot-extended-after-insurer-pushback/ 2026-04-22T16:19:19Z Pharminent en Medicare obesity drug pilot extended after insurer pushback 2026-04-22T09:27:37Z Blog https://pharminent.com/health-canada-approves-biocons-two-denosumab-biosimilars-2/ 2026-04-22T16:19:20Z Pharminent en Health Canada approves Biocon's two denosumab biosimilars 2026-04-22T07:35:53Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-april-21-2026/ 2026-04-21T21:28:03Z Pharminent en Oncology Intelligence Digest • April 21, 2026 2026-04-21T21:27:59Z Blog https://pharminent.com/tortugas-debuts-with-106m-and-brain-drugs-from-hansoh-eisai/ 2026-04-22T16:19:21Z Pharminent en Tortugas debuts with $106M and brain drugs from Hansoh, Eisai 2026-04-21T18:14:00Z Blog https://pharminent.com/mercks-fast-ascending-kidney-cancer-drug-hits-a-setback/ 2026-04-22T16:19:21Z Pharminent en Merck's fast-ascending kidney cancer drug hits a setback 2026-04-21T17:39:00Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-april-21-2026/ 2026-04-21T17:29:55Z Pharminent en Strategic News Watch • April 21, 2026 2026-04-21T17:29:51Z Blog https://pharminent.com/bioage-says-early-data-suggest-best-in-class-potential-for-inflammation-drug/ 2026-04-21T17:03:46Z Pharminent en BioAge says early data suggest 'best-in-class' potential for inflammation drug 2026-04-21T15:19:00Z Blog https://pharminent.com/tortugas-takes-neuro-deep-dive-with-106m-to-develop-eisai-hansoh-programs/ 2026-04-21T17:03:48Z Pharminent en Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs 2026-04-21T14:31:02Z Blog https://pharminent.com/merck-eisais-keytruda-triplet-fails-to-improve-survival-in-kidney-cancer/ 2026-04-21T17:03:51Z Pharminent en Merck, Eisai's Keytruda triplet fails to improve survival in kidney cancer 2026-04-21T13:32:08Z Blog https://pharminent.com/novo-nordisk-preps-filings-for-sickle-cell-drug-etavopivat/ 2026-04-21T17:03:53Z Pharminent en Novo Nordisk preps filings for sickle cell drug etavopivat 2026-04-21T13:26:13Z Blog https://pharminent.com/aacr-2026-moderna-revolution-zymeworks-and-beone-showcase-new-data/ 2026-04-21T17:03:55Z Pharminent en AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data 2026-04-21T13:14:14Z Blog https://pharminent.com/msd-eisai-report-setback-in-first-line-kidney-cancer-trial/ 2026-04-21T17:03:56Z Pharminent en MSD, Eisai report setback in first-line kidney cancer trial 2026-04-21T12:39:29Z Blog https://pharminent.com/gilead-arcus-tumble-again-in-tigit-triggering-2-trial-culls/ 2026-04-21T17:03:57Z Pharminent en Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls 2026-04-21T12:27:14Z Blog https://pharminent.com/jazz-and-lilly-cancer-drugs-cleared-for-use-by-nhs/ 2026-04-21T17:03:57Z Pharminent en Jazz and Lilly cancer drugs cleared for use by NHS 2026-04-21T11:28:02Z Blog https://pharminent.com/the-top-15-specialty-pharmacies-of-2025-pbm-affiliated-pharmacies-dominate-while-health-systems-and-independents-gain-ground/ 2026-04-21T17:03:59Z Pharminent en The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground 2026-04-21T11:00:00Z Blog https://pharminent.com/serif-flagships-latest-biotech-aims-to-make-a-new-kind-of-genetic-medicine/ 2026-04-21T17:04:00Z Pharminent en Serif, Flagship's latest biotech, aims to make a new kind of genetic medicine 2026-04-21T10:30:00Z Blog https://pharminent.com/fda-kicks-off-review-of-roches-gazyva-for-wider-lupus-use/ 2026-04-21T17:04:02Z Pharminent en FDA kicks off review of Roche's Gazyva for wider lupus use 2026-04-21T10:20:39Z Blog https://pharminent.com/pfizer-and-astellas-secure-fda-priority-review-for-padcev-mibc-combo-therapy/ 2026-04-21T17:04:02Z Pharminent en Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy 2026-04-21T10:07:04Z Blog https://pharminent.com/eli-lilly-doubles-down-on-in-vivo-with-7bn-kelonia-buyout/ 2026-04-21T17:04:03Z Pharminent en Eli Lilly doubles down on in vivo with $7bn Kelonia buyout 2026-04-21T10:05:53Z Blog https://pharminent.com/asahi-kasei-acquires-german-company-aicuris/ 2026-04-21T17:04:03Z Pharminent en Asahi Kasei acquires German company Aicuris 2026-04-21T09:39:16Z Blog https://pharminent.com/pfizer-and-astellas-secure-fda-priority-review-for-padcev-mibc-combo-therapy-2/ 2026-04-21T17:04:03Z Pharminent en Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy 2026-04-21T09:35:56Z Blog https://pharminent.com/italy-leads-the-way-on-child-genetic-disease-diagnosis/ 2026-04-21T17:04:04Z Pharminent en Italy leads the way on child genetic disease diagnosis 2026-04-21T09:35:44Z Blog https://pharminent.com/asahi-kasei-acquires-german-company-aicuris-2/ 2026-04-21T17:04:06Z Pharminent en Asahi Kasei acquires German company Aicuris 2026-04-21T08:34:42Z Blog https://pharminent.com/trump-executive-order-lifts-psychedelics-biotechs/ 2026-04-21T17:04:06Z Pharminent en Trump executive order lifts psychedelics biotechs 2026-04-21T05:00:00Z Blog